An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers and of BI 754111 Monotherapy With Subsequent Combination With BI 754091 in Patients With Follicular Lymphoma, Followed by an Expansion Cohort at the RPIID of the Combination in Patients With Non-small Cell Lung Cancer

Trial Profile

An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers and of BI 754111 Monotherapy With Subsequent Combination With BI 754091 in Patients With Follicular Lymphoma, Followed by an Expansion Cohort at the RPIID of the Combination in Patients With Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2017

At a glance

  • Drugs BI 754091 (Primary) ; BI 754111 (Primary)
  • Indications Follicular lymphoma; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 27 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 01 Jun 2017 Planned initiation date changed from 22 May 2017 to 2 Jun 2017.
    • 22 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top